Can MitoQ Rejuvenate Vascular Function in Healthy Older Adults?

Written by Georgia Truman (MSc), Molecular and Cellular Biology. Reviewed by Dr. Siobhan Mitchell (PhD), Neuroscience.

Meta Description: Analysis of a 6-week crossover trial: How chronic supplementation with mitochondria-targeted antioxidants influences endothelial function and arterial stiffness in aging populations.

Vascular aging is a primary precursor to cardiovascular disease (CVD), characterized by a decline in endothelial-dependent dilation (EDD). This decline is largely driven by a reduction in nitric oxide (NO) bioavailability, caused by excess mitochondrial-derived reactive oxygen species (mtROS). Researchers hypothesized that chronic MitoQ supplementation could "rejuvenate" blood vessels by quenching this oxidative stress at the source.

What you’ll learn:

• The magnitude of improvement in brachial artery flow-mediated dilation (BAFMD).

• The effect of 20mg daily doses on aortic pulse wave velocity (PWV).

• MitoQ’s influence on circulating markers of oxidative stress like oxidized LDL.

What was the impact of MitoQ on arterial dilation and stiffness?

In this 6-week randomized, double-blind crossover trial, 20 healthy adults (60–79 years) took 20mg of MitoQ daily. The primary outcome was a 42% improvement in BAFMD (P<0.05). Furthermore, in a subgroup of participants who entered the study with elevated arterial stiffness, MitoQ significantly reduced aortic pulse wave velocity (PWV).

How does this research support the mitochondrial theory of vascular aging?

To confirm the mechanism, researchers administered an acute supratherapeutic dose (160mg). This acute challenge improved FMD in participants after the placebo phase but failed to provide an additional boost after the 6-week MitoQ phase, suggesting that chronic supplementation had already successfully suppressed the mtROS-mediated impairment of endothelial function. This provides robust in vivo evidence that mitochondria are a central therapeutic target for vascular health.

What are the clinical implications for practitioners?

The 42% improvement in FMD is clinically significant; a 1% improvement in this metric is typically associated with a 13% reduction in CVD risk. Practitioners should note that MitoQ reduced oxidized LDL by 13% but did not alter systemic inflammatory markers like IL-6 or CRP, indicating its effects are specifically targeted to mitochondrial redox balance rather than broad systemic inflammation.

DOI: 10.1161/HYPERTENSIONAHA.117.10787